Business Context and Reporting Period
This Form 8-K Current Report was filed by Matinas Biopharma Holdings, Inc. on December 23, 2014. The report details regulatory feedback received from the U.S. Food and Drug Administration (FDA) regarding the Company's Investigational New Drug (IND) application for its lead drug candidate, MAT9001, intended for the treatment of severe hypertriglyceridemia.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures. However, it discloses a critical liquidity requirement: the Company estimates it needs to raise between $20.0 million and $60.0 million in additional financing to initiate and complete its Phase III clinical program and submit a New Drug Application (NDA). The Company currently has no arrangements or credit facilities in place to secure these funds.
Material Changes and Regulatory Updates
- FDA Feedback: The FDA did not place a clinical hold on MAT9001 but recommended revisions to the planned four-week rat comparative bridging toxicity study and the 4-way crossover single dose Fed/Fast PK study.
- Timeline Impact: Previously, the Company planned to run these studies concurrently with its Phase III clinical study. Due to FDA recommendations, the Company now intends to submit modified protocols for the toxicity and PK studies in early Q1 2015. These studies must be completed and reviewed by the FDA before dosing can begin in the Phase III trial.
- Delay Risk: There is a risk of delay in the commencement of the Phase III clinical study if the Company cannot meet with the FDA in a timely fashion or if the revised studies take longer than anticipated.
Outlook, Risks, and Contingencies
Management's outlook is contingent upon securing significant capital and navigating regulatory timelines. Key risks and contingencies include:
- Capital Raising: There is no assurance the Company can raise the required $20.0 to $60.0 million on acceptable terms or at all.
- Development Stage: MAT9001 remains in development and is not available for sale.
- Forward-Looking Statements: The filing contains numerous forward-looking statements regarding product development, clinical timelines, and market opportunity, which are subject to significant risks and uncertainties, including regulatory approval delays and competition.
Investor Verification Checklist
- Verify the Company's current cash position and runway to determine the urgency of the $20.0 to $60.0 million financing need.
- Monitor the submission of modified protocols for the rat toxicity and PK studies in Q1 2015.
- Track any announcements regarding the successful raising of additional capital.
- Review subsequent FDA communications regarding the revised study protocols and the final Phase III clinical trial design.